Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Quinuclidinone SCHEMBL6857718 | 0.98 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2KDM4EMAPK1MAPT | |
| Methylene Quinuclidinone SCHEMBL2229287 | 0.98 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2KDM4EMAPK1MAPT | |
| Methylene Quinuclidinone SCHEMBL4958476 | 0.95 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2KDM4EMAPK1MAPT | |
| SCHEMBL21884070 | 0.91 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2KDM4EMAPK1MAPT | |
| SCHEMBL3182637 | 0.61 | DAO (0.33) | — | |
| SCHEMBL9604254 | 0.57 | MEN1 (0.31) | MAPTKMT2AMEN1 | |
| SCHEMBL9350493 | 0.56 | DAO (0.31) | — | |
| SCHEMBL10631548 | 0.53 | ENO1 (0.34) | ALDH1A1SMN1; SMN2KDM4EMAPTKMT2A | |
| SCHEMBL8872584 | 0.53 | — | — | |
| SCHEMBL21335045 | 0.52 | DAO (0.39) | ALDH1A1MAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119264107-A | Ionic liquid based on mefloquine and artesunate and preparation of sustained-release suppository thereof | 四川大学 | 2025-01-07 | — | — | CN | claimed |
| WO-2023017179-A1 | METHYLENE QUINUCLIDINONE COMPANION DIAGNOSTICS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-02-16 | — | — | WO | claimed |
| EP-4134671-A1 | METHYLENE QUINUCLIDINONE COMPANION DIAGNOSTICS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-02-15 | — | — | EP | claimed |
| EP-4066302-A1 | STABLE AQUEOUS COMPOSITIONS COMPRISING QUINONES, AND USE THEREOF IN REDOX FLOW BATTERIES | Technische Universität Graz (AT) | 2022-10-05 | — | — | EP | claimed |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2017-06-15 | — | — | US | claimed |
| EP-3125940-A2 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2017-02-08 | — | — | EP | claimed |
| WO-2015150472-A2 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2015-10-08 | — | — | WO | claimed |
| US-20110184175-A1 | METHOD FOR PRODUCING BSH DERIVATIVE AND BSH DERIVATIVE | STELLA PHARMA CORPORATION (JP) | 2011-07-28 | — | — | US | claimed |
| EP-2319849-A1 | METHOD FOR PRODUCING BSH DERIVATIVE AND BSH DERIVATIVE | Stella Pharma Corporation (JP) | 2011-05-11 | — | — | EP | claimed |
| EP-1605939-B1 | PHARMACEUTICAL USE OF 1-AZABICYCLO¬ 2.2.2 OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2008-10-15 | — | — | EP | claimed |
| EP-1605939-A1 | PHARMACEUTICAL USE OF 1-AZABICYCLO[ 2.2.2] OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2005-12-21 | — | — | EP | claimed |
| US-20050090510-A1 | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | APREA THERAPEUTICS AB (SE) | 2005-04-28 | — | — | US | claimed |
| EP-1476166-A1 | USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES | APREA AB (SE) | 2004-11-17 | — | — | EP | claimed |
| WO-2004084893-A1 | PHARMACEUTICAL USE OF 1-AZABICYCLO[2.2.2]OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2004-10-07 | — | — | WO | claimed |
| WO-2003070250-A1 | USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES | APREA AB (SE) | 2003-08-28 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673782-B1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORP (US) | 2000-06-14 | — | — | EP | claimed |
| US-4309544-A | CONDENSATION OF 2-METHYLENE-QUINUCLIDIN-3-ONE WITH A KETONE OR AN | THE PURDUE FREDERICK COMPANY (US) | 1982-01-05 | — | — | US | claimed |
| US-4226996-A | 4-SUBSTITUTED-6-OXA-1-AZATRICYCLO/4.2.2.0.2.7/DODECAN-5-ONE SALT | THE PURDUE FREDERICK COMPANY (US) | 1980-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184175-A1 | METHOD FOR PRODUCING BSH DERIVATIVE AND BSH DERIVATIVE | CBS, DBH, CTH | ALDH1A1 1068/4885SMN1; SMN2 2165/4885KDM4E 4071/4885 |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | TP53, BRAF, TP53BP1 | ALDH1A1 2918/4885SMN1; SMN2 4357/4885KDM4E 3406/4885 |
| US-20050090510-A1 | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | TP53, ACP1, TP53BP1 | ALDH1A1 3246/4885SMN1; SMN2 4008/4885KDM4E 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.